Breckenridge Pharmaceutical, Inc. is recalling 570,296 bottles of Duloxetine Delayed-Release Capsules (20mg, 30mg, and 60mg) because they contain an impurity called N-nitroso-duloxetine at levels higher than the FDA's recommended limit. Duloxetine is a prescription medication used to treat depression, anxiety, and certain types of nerve and muscle pain. Consumers should continue taking their medication until they speak with a doctor or pharmacist, as stopping suddenly can cause health issues.
The capsules contain N-nitroso-duloxetine, which is a type of nitrosamine impurity. Nitrosamines are classified as probable human carcinogens, meaning that long-term exposure to levels above the safety limit may increase the risk of developing cancer.
You have 2 options:
Distributed in 90-count and 1,000-count bottles.
Distributed in 500-count bottles.
Distributed in 90-count bottles.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.